Europe’s largest pharmaceutical firm, Novo Nordisk, has announced that it will offer its most popular weight-loss drug, Wegovy, for less than half of its listed price. This follows a similar ...

Competition from Him & Hers Health seems to be weighing on Novo Nordisk's stock. A half-hearted rating from Morgan Stanley yesterday isn't cheering investors up very much at all. Yet a new study ...

Novo Nordisk stock has fallen roughly 40% from a peak it reached last June. The U.S. Food and Drug Administration recently confirmed Novo Nordisk is producing enough Ozempic and Wegovy to meet ...

Danish drugmaker Novo Nordisk (NVO) said Wednesday that it will drop prices 23% for all doses of Wegovy. The new monthly price of $499, down from $650, takes effect immediately. Novo said the new ...

Novo Nordisk is cutting the cost of its blockbuster weight-loss drug Wegovy in half for U.S. patients paying cash through its direct-to-patient online pharmacy, as competition in the highly ...

Less than two weeks after Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk said Wednesday it would cut the price of its popular weight-loss drug Wegovy ...

Novo Nordisk (NVO) announced a new cash-pay option for its blockbuster weight-loss drug Wegovy, offering a monthly dose at $499 and home delivery. The move follows competitor Eli Lilly (LLY ...

Novo Nordisk is cutting the price of its weight-loss drug Wegovy to $499 per month for cash-paying customers who buy through its NovoCare Pharmacy. The discounted price is aimed at uninsured ...

Novo Nordisk will start selling its obesity drug Wegovy directly to patients at a reduced price, following a similar move from Eli Lilly as the two drugmakers compete for market share and try to ...

After its potential kidney disease drug went down in flames late last year, Novo Nordisk is pinning the blame on alleged fraudulent claims by the drug’s original maker. The Danish pharma giant ...

Feb 18 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab is seeking up to $830 million in damages from KBP Biosciences, according to a ruling by a Singapore court, as the Danish drugmaker says it ...